A detailed history of Aigen Investment Management, LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Aigen Investment Management, LP holds 5,948 shares of NBIX stock, worth $743,500. This represents 0.14% of its overall portfolio holdings.

Number of Shares
5,948
Holding current value
$743,500
% of portfolio
0.14%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$114.58 - $153.15 $681,521 - $910,936
5,948 New
5,948 $684,000
Q1 2024

May 14, 2024

BUY
$130.4 - $143.74 $626,050 - $690,095
4,801 New
4,801 $662,000
Q3 2022

Nov 09, 2022

BUY
$92.03 - $107.81 $2.32 Million - $2.71 Million
25,157 New
25,157 $2.67 Million
Q1 2022

May 05, 2022

SELL
$72.45 - $94.81 $205,540 - $268,975
-2,837 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$79.65 - $106.22 $225,967 - $301,346
2,837 New
2,837 $233,000
Q3 2021

Nov 12, 2021

SELL
$86.18 - $99.03 $672,721 - $773,028
-7,806 Closed
0 $0
Q2 2021

Aug 10, 2021

BUY
$89.43 - $102.27 $212,664 - $243,198
2,378 Added 43.81%
7,806 $760,000
Q1 2021

May 11, 2021

BUY
$87.57 - $119.4 $475,329 - $648,103
5,428 New
5,428 $528,000
Q4 2020

Feb 12, 2021

SELL
$86.91 - $108.33 $602,894 - $751,485
-6,937 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$96.16 - $135.15 $323,289 - $454,374
3,362 Added 94.04%
6,937 $667,000
Q2 2020

Aug 10, 2020

SELL
$85.09 - $130.36 $370,056 - $566,935
-4,349 Reduced 54.88%
3,575 $436,000
Q1 2020

May 08, 2020

SELL
$75.11 - $113.76 $103,201 - $156,306
-1,374 Reduced 14.78%
7,924 $686,000
Q4 2019

Feb 04, 2020

BUY
$86.8 - $118.57 $807,066 - $1.1 Million
9,298 New
9,298 $999,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Aigen Investment Management, LP Portfolio

Follow Aigen Investment Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Aigen Investment Management, LP with notifications on news.